title: Is sustained pain freedom and no adverse events a clinically relevant endpoint in acute migraine treatment?
authors.forename: Peer
authors.initials: P
authors.lastname: Tfelt-Hansen
mesh_terms: D000700:Analgesics / Q000009:adverse effects*; D001381:Azepines / Q000009:adverse effects*; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D023303:Oxazolidinones / Q000009:adverse effects*; D012107:Research Design; D014363:Tryptamines / Q000009:adverse effects*
chemical_list: D000700:Analgesics; D001381:Azepines; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D007093:Imidazoles; D023303:Oxazolidinones; D014363:Tryptamines